Immunosuppressants to Postoperative Infection and Death

Sponsor
Chung Shan Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06121804
Collaborator
(none)
20,000
1
36
555.4

Study Details

Study Description

Brief Summary

The goal of this observational study is to explore the different immunosuppressive agents and related outcomes in organ transplantation patients in Taiwan. The main question it aims to answer is the risk of different immunosuppressive agents for infection and survival after transplant.

The study enrolled patients who underwent solid organ transplant (SOT), kidney (ICD-9-CM code V42.0), liver (ICD-9-CM code V42.7), or lung (ICD-9-CM code V42.6) transplants. We employed propensity score matching (PSM) to establish a matched cohort. The study will compare SOT patients and general patients to explore the risk of different immunosuppressive agents for infection and survival.

Condition or Disease Intervention/Treatment Phase
  • Drug: Immunosuppressive Agents

Detailed Description

This study used secondary data from the Longitudinal Health Insurance Database (LHID), a subset of the NHIRD provided by the Health and Welfare Data Science Center (HWDC) of the Ministry of Health and Welfare in Taiwan.

The HWDC encrypts personally identifying data to protect the privacy of beneficiaries. The database includes detailed clinical records from both the inpatient and outpatient claims of the beneficiaries of Taiwan's National Health Insurance program. This program has provided coverage for up to 99% of the country's population since 1995. The NHIRD can serve as a foundation for the procurement of real-world evidence to support clinical decisions and health-care policy-making.

Diagnostic data within the NHIRD from before 2016 and from 2016 or later are respectively coded using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes.

The database was provided by the HWDC under license and so cannot be made freely available. Requests for access to these data should be made to HWDC (https://dep.mohw.gov.tw/dos/cp-5119-59201-113.html).

Study Design

Study Type:
Observational
Anticipated Enrollment :
20000 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
The Cost-effectiveness Analysis of Immunosuppressants to Postoperative Infection and Death in the Patients With Organ Transplantation
Actual Study Start Date :
Dec 20, 2021
Anticipated Primary Completion Date :
Nov 20, 2024
Anticipated Study Completion Date :
Dec 20, 2024

Arms and Interventions

Arm Intervention/Treatment
Patients with organ transplantation

Patients who underwent SOTs between 2002 and 2013, specifically, kidney (ICD-9-CM code V42.0), liver (ICD-9-CM code V42.7), or lung (ICD-9-CM code V42.6) transplants.

Drug: Immunosuppressive Agents
Prescribing immunosuppressive agents

Patients without organ transplantation

The general patients were enrolled as the comparison. We used propensity score matching (PSM) to establish a matched cohort.

Drug: Immunosuppressive Agents
Prescribing immunosuppressive agents

Outcome Measures

Primary Outcome Measures

  1. Postoperative infection [From the date of underwent SOTs until the date of incident infection or date of death from any cause, whichever came first, assessed up to 5 years.]

    Postoperative infection contains Pneumocystis jiroveci pneumonia, cytomegalovirus disease, and Herpes simplex virus

  2. Death [From the date of underwent SOTs until the date of death from any cause, assessed up to 5 years.]

    Death

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients who underwent solid organ transplant (SOT)
Exclusion Criteria:
  • Patients who received more than one SOT, had an infectious disease diagnosis before their SOT or had incomplete medical information in the database.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chung Shan Medical University Taichung Taiwan 40201

Sponsors and Collaborators

  • Chung Shan Medical University

Investigators

  • Study Chair: Chien-Ying Lee, PhD, Chung Shan Medical University

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Chung Shan Medical University
ClinicalTrials.gov Identifier:
NCT06121804
Other Study ID Numbers:
  • CS2-21134
First Posted:
Nov 8, 2023
Last Update Posted:
Nov 8, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 8, 2023